Association of<i>Helicobacter pylori</i>infection with diabetic complications: a meta-analysis

Wang, Rui; Fu, Yakun; Lv, Zhen

doi:10.3109/07435800.2013.794426

Cited by 21 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, 3036 articles that met our search criteria were first identified from the seven databases. Sixty articles9–18 27–76 of observational studies were finally selected, covering 88 unique outcomes (figure 1). Fifty-four meta-analyses10–17 28–34 38–40 42–44 47–50 54–60 64–70 72–75 were reanalysed because they did not present all of the results of estimates (i.e.…”

Section: Resultsmentioning

confidence: 99%

Association betweenH. pyloriinfection and health Outcomes: an umbrella review of systematic reviews and meta-analyses

Tan

Liu

et al. 2020

BMJ Open

View full text Add to dashboard Cite

ObjectiveSystematic reviews and meta-analyses have revealed the associations betweenH. pyloriinfection and various health outcomes. We aimed to evaluate the strength and breadth of evidence on the associations.DesignUmbrella review of systematic reviews and meta-analyses.SettingNo settings.ParticipantsNo patients involved.Data sourcesEmbase, PubMed, Web of Science, Cochrane Library Databases, CNKI, VIP database and Wangfang database from inception to February 1, 2019.Outcomes measuresDiverse diseases (such as cancer and ischaemic heart disease).ResultsSixty articles reporting 88 unique outcomes met the eligible criteria. 74 unique outcomes had nominal significance (p<0.05). Of the outcomes with significance, 61 had harmful associations and 13 had beneficial associations. Furthermore, 73% (64) of the outcomes exhibited significant heterogeneity . Of the these meta-analyses, 32 had moderate to high heterogeneity (I2=50%–75%) and 24 had high heterogeneity (I2>75%). Moreover, 20% exhibited publication bias (p<0.1). In addition, 97% of the methodological qualities were rated ‘critically low’. 36% of the evidence qualities of outcomes were rated ‘low’, 56% of the evidence qualities were rated ‘very low’ and 8% of the evidence qualities were rated ‘moderate’.H. pyloriinfection may be associated with an increased risk of five diseases and a decreased risk of irritable bowel syndrome.ConclusionAlthough 60 meta-analyses explored 88 unique outcomes, moderate quality evidence only existed for six outcomes with statistical significance.H. pyloriinfection may be associated with a decreased risk of irritable bowel syndrome and an increased risk of hypertriglyceridemia, chronic cholecystitis and cholelithiasis, gestational diabetes mellitus, gastric cancer and systemic sclerosis.Trial registrationCRD42019124680.

show abstract

Section: Resultsmentioning

confidence: 99%

Association betweenH. pyloriinfection and health Outcomes: an umbrella review of systematic reviews and meta-analyses

Tan

Liu

et al. 2020

BMJ Open

View full text Add to dashboard Cite

show abstract

“…The H. pylori infection rate has been reported to be significantly higher in patients with DM, particularly in those with type 2 DM (T2DM) . H. pylori infection has been reported to increase the risk for onset and progression of T2DM, as well as complications . However, a recent meta‐analysis reported that no solid evidence is available for the worsening of T2DM control by H. pylori infection, and no consensus has been reached.…”

Section: Indicationsmentioning

confidence: 99%

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

et al. 2019

View full text Add to dashboard Cite

Background Since “Helicobacter pylori (H. pylori) infection” was set as the indication in the Japanese Society for Helicobacter Research (JSHR) Guidelines 2009, eradication treatment for H. pylori gastritis is covered under insurance since 2013 in Japan, and the number of H. pylori eradication has rapidly increased. Under such circumstances, JSHR has made the third revision to the “Guidelines for diagnosis and treatment of H. pylori infection” for the first time in 7 years. Methods The Guideline Committee held 10 meetings. Articles published between the establishment of the 2009 Guidelines and March 2016 were reviewed and classified according to the evidence level; the statements were revised on the basis of this review. After inviting public comments, the revised statements were finalized using the Delphi method. Results There was no change in the basic policy that H. pylori infectious disease is an indication for eradication. Other diseases presumed to be associated with H. pylori infection were added as indications. Serum pepsinogen level, endoscopic examination, and X‐ray examination were added to the diagnostic methods. The effects of 1‐week triple therapy consisting of potassium‐competitive acid blocker (P‐CAB), amoxicillin, and clarithromycin have improved, and high eradication rates can also be expected with proton pump inhibitors (PPI) or P‐CAB combined with amoxicillin and metronidazole. If the susceptibility test is not performed, the triple PPI or P‐CAB/amoxicillin/metronidazole therapy should be chosen, because the PPI/amoxicillin/metronidazole combination demonstrated a significantly higher eradication rate than PPI/amoxicillin/clarithromycin. In the proposal for gastric cancer prevention, we divided gastric cancer prevention measures by age from adolescent to elderly, who are at an increased gastric cancer risk, and presented measures for gastric cancer prevention primarily based on H. pylori eradication. Conclusion We expect the revised guidelines to facilitate appropriate interventions for patients with H. pylori infection and accomplish its eradication and prevention of gastric cancer.

show abstract

“…A meta‐analysis by Wang et al. showed a possible association between H. pylori and the risk of nephropathy (RR: 1.35, 95% CI: 1.06–1.73) and neuropathy (RR: 1.73, 95% CI: 1.03–1.40), especially in Asian patients. Similar results were obtained in a similar study showing a positive correlation between H. pylori infection and nephropathy in DM patients .…”

Section: Diabetes Mellitusmentioning

confidence: 99%

Helicobacter pylori and Extragastric Diseases

Franceschi¹,

Tortora

Gasbarrini³

et al. 2014

Helicobacter

124

View full text Add to dashboard Cite

While Helicobacter pylori infection was initially revealed to be associated only with some gastroduodenal diseases, further studies have shown its possible role in several extragastric diseases. For idiopathic thrombocytopenic purpura, sideropenic anemia, and vitamin B12 deficiency, the diagnosis of H. pylori infection is recommended, and there are many other conditions such as cardiovascular, neurological, dermatological, and respiratory diseases in which H. pylori may possibly play a role. Interestingly, a potential role has also been described for GI neoplastic diseases, including colorectal and pancreatic cancer. Different mechanisms of action have been proposed, ranging from the induction of a low grade inflammatory state to the occurrence of molecular mimicry mechanisms. This review summarizes the results of the most relevant studies published on this topic over the last year.

show abstract

Association ofHelicobacter pyloriinfection with diabetic complications: a meta-analysis

Abstract: Our meta-analyses suggest a possible relationship between HP and the risk of nephropathy and neuropathy. Our results also suggest that the effect of HP on the risk of nephropathy is stronger in Oriental people and in type 2 DM patients.

Cited by 21 publications

References 28 publications

Association betweenH. pyloriinfection and health Outcomes: an umbrella review of systematic reviews and meta-analyses

Association betweenH. pyloriinfection and health Outcomes: an umbrella review of systematic reviews and meta-analyses

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

Helicobacter pylori and Extragastric Diseases

Contact Info

Product

Resources

About